Who research peptides are not for.
Research-use-only material was manufactured, documented and sold for laboratory research. No regulator has assessed it for use in people, no prescriber has judged it against your history, and no pharmacy has checked it against anything else you take. Those are not formalities — they are the things that are missing.
What follows is not a list of conditions. It is a list of positions: facts about the material's status, populations the published literature itself leaves out, and the absence of the relationship that would make any of it answerable. 9 of the compounds in the dosing reference carry an explicit caution in their own source notes, reproduced on each compound's page rather than summarised here.
This is the central one. Research-use material was not assessed for use in people, is not dispensed by a pharmacy, and carries no prescriber who has looked at you. Deciding to use it yourself means taking on the whole question of safety and appropriateness alone, with laboratory paperwork that was never designed to answer it.
Research material is sold to adults, and the questions it raises are not ones a minor should be navigating alone or on the strength of a website. Royal Empire Supply requires an age attestation for the same reason.
The published literature excludes these groups from much of what has been studied, and several compounds in the dosing reference carry that exclusion explicitly in their own source notes. Where the evidence deliberately does not extend, the honest answer is that nothing is known rather than that nothing is wrong.
Interactions are the risk that is invisible until it is not. A prescriber or pharmacist can check one substance against everything else you take; a reference table cannot, because it does not know what else is on the list.
A condition under treatment is a condition somebody is responsible for. Adding an unassessed material to that picture without the person managing it is how a treatment that was working stops being understood.
This library reports what has been published, with its sources credited and its cautions intact. It does not recommend, and it is not positioned to: it is funded by a company that sells the material, which is disclosed on every page precisely so you can weigh it. A reference that recommends its funder's product has stopped being a reference.
What to take to a clinician.
“Talk to a provider” is advice most readers have already heard and rarely acted on, usually because they do not know what the conversation would consist of. This is what makes it a short one.
- 01The specific compound, written as its full name rather than an abbreviation, and the vial size if you have it.
- 02What you have actually read, and where — the published source rather than a summary of it.
- 03Everything else you take, prescribed or not, including supplements.
- 04What you are hoping would change, stated as a question rather than a plan.
- 05What would make you stop, decided before you start rather than during.
If you are a researcher or a licensed clinician, the other half of this is who research material is for. Everything in this library is educational and is funded by a company that sells the material, which is disclosed on every page so you can weigh it.